Mobilise-D Patient and Public Information Pack
The PPAG has worked with some of our researchers to develop a document that explains the project and its aims to anyone who may be interested in it. Read more HERE.
Mobilise-D Public Newsletter Jan-Aug 2021
Stay up to date on what has happened in Mobilise-D over the last few months. This newsletter consists of all our news from January to August 2021. Read it HERE.
Novartis job opportunity for analysis of wearable sensor data for Digital Mobility Outcomes
Novartis is now looking for a Digital Data Scientist to join their group and participate in their ground-breaking medical research activities that redefine the grammar for medicine in the post-genome era. Read more HERE.
Episode 4: The Cyclone Challenge – Mobiliser Raising Money for PD UK
The day had finally arrived. The day for the Cyclone Challenge Ride. Saturday, July 03, the day mobiliser Alison Yarnall and her friend Naomi were going to ride their bicycles for 108 miles (173,8 km). The day they wanted to raise money for a good cause. The day they raised money for Parkinson’s UK. Read more HERE.
Mobilise-D Workshop at the IEEE BHI-BSN Conference: Real-world Digital Mobility Assessment
Our Mobilisers Andrea Cereatti, Silvia Del Din and Felix Kluge will organize a workshop on “Real-world digital mobility assessment” at the virtual IEEE International Conference on Biomedical and Health Informatics at the end of July. Read more HERE.
ISB2021 Mobilise-D Tutorial: Translating Movement Analysis Beyond the Laboratory with Wearable Sensors
The Congress of the International Society of Biomechanics (ISB) will be held from July 25-29, 2021. On Sunday, July 25, 09:30-11:30, our Mobilise-D colleagues Andrea Cereatti, Silvia Del Din, and Kamiar Aminian will have a tutorial: “To wear or not to wear? Translating Movement Analysis Beyond the Laboratory with Wearable Sensors”. Read more HERE.
Episode 3: Making a difference in people’s lives – Silvia Del Din awarded a NUAcT Fellowship.
Our Mobilise-D colleague Dr. Silvia Del-Din has always been fascinated by research and the idea of “making a difference in people’s lives”. Here she explains her role in Mobilise-D, her new NUAcT fellowship at Newcastle University, and her perspective on how remote monitoring can revolutionize healthcare. Read more HERE.
Key challenges in the use & development of digital endpoints from a health technology assessment (HTA) perspective
Digital endpoints offer a great potential to be considered in the HTA framework. So far, however, there is no institutional way in. On February 15, 2021, IMI Neuronet hosted an online meeting on health technology assessment (HTA) and regulatory interactions. The discussions were based on the experiences of three different IMI projects that are developing digital endpoints for use in clinical trials, including Mobilise-D. To support the discussions, three international HTA experts that represent different organisations were invited to provide their perspectives on several important issues. Read more HERE.
IMI article about our Digital Health Catalyst initiative
The Digital Health Catalyst (DHC) was created by Mobilise-D and IDEA-FAST in response to the growing need for research and application in the area of real-world digital measurements. Read more HERE.
When life gives you lemons, make Lemon Drizzle cake!
Real World Stories – Episode 3: “My balance is elusive advanced Multiple Sclerosis (MS). Always optimistic. Want to walk at least 25 times a month for eight months #2021Walkathon. Love my Travelscoot (The Trike)”. This is the Twitter bio of “Patrick Burke, I walk very slowly”, the inspiration behind the third episode of our Real World Stories.
An INSIGHT into public engagement: Interview with PhD student Cameron Kirk
In the Spotlight: This is exactly what drove me to apply for the INSIGHTS doctoral public lecture prize at Newcastle University, UK. This prize was competed by all post-graduate students within the university, and we had to create a presentation that explains our PhD research to the public, in as clear a manner as possible. I was a runner up for the award, and here is an excerpt from an interview I had with the INSIGHTS team, in the build-up for the event.
It’s a kind of magic: the validation study has been Mobilise-D against all odds
We invited one of our Mobilisers working in WP2 Algorithm Development and Technical Validation, Kirsty Scott, to share some of the daunting yet exciting experiences of being part of the team and how they are managing to conduct the Technical Validation Study in Mobilise-D in COVID-19 times. Read more.
– It’s great to exercise myself together with my groups
Real World Stories – Episode 2: “I’ve always been passionate about exercising; I’ve taken a lot of instructor courses. To be able to work as a volunteer, as we all do in Strong and Steady, is a great offer and again, with MS, it’s great to exercise me together with my groups. That’s quality of life!” Read the full episode here.
[Public Newsletter 2020]
Last year was a turbulent and busy year for Mobilise-D in many ways, and this Public Newsletter highlights some of the most significant news from 2020. Read our Public Newsletter 2020 here.
Mobilise-D and IDEA-FAST join forces to strengthen research and development of digital biomarkers
From January 2021 onwards, Mobilise-D and IDEA-FAST, two ongoing EU Innovative Medicines Initiatives projects, will join forces to increase the impact and the benefits of digital health technologies developed by both projects.
A little seasonal greeting as we look forward to saying goodbye to 2020 and welcome 2021!
Enjoy a safe, happy and healthy holiday season and all the very best for the new year.
Original text and music: Pentatonix
Arrangement: Gunnhild Breirem
This coming Friday Abolfazl Soltani, one of our Mobilisers from EPFL, Switzerland, will have the public defense of his PhD thesis. This will be a more popular presentation of his work for the general public. Read more on how you can follow the public defense here.
In the first year of Mobilise-D, we asked the European Medicines Agency (EMA) for qualification advice for Digital Mobility Outcomes (DMOs). EMA just published their letter of support that publicly endorses our initial stage in the wider objective of the Mobilise-D Consortium to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of mobility performance in regulatory drug trials. We have now got support to continue our work towards regulatory approval of DMOs as biomarkers! You can read the full letter of support here.
Monitoring patients’ mobility during the COVID19 pandemic could easily have been impossible due to lockdown and restrictions such as social distancing. However, this isn’t the case for the Mobilise-D technical validation study (TVS) where 120 participants with chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, congestive heart failure, or hip fracture, along with healthy older adults, will be enrolled. Our test sites in Newcastle and Sheffield have found a way to work around the distancing restrictions to keep the study open, and confirmed that the technical validation study testing will continue despite the 2nd lockdown in the UK.
Measuring real-world mobility outside the lab with a Gold Standard system is no mean feat. Our Mobilise-D partners at the University of Sassari in Sardinia (UNISS) have developed the INDIP system which is currently being used in the ongoing technical validation study. But for the INDIP to work smoothly at our test sites in the UK, Germany, and Israel, a lot of hard work is necessary from many people. In this video, you get a small peek behind the scenes at UNISS.
Real World Stories – Episode 1: Mobility – how well people walk – is an important marker of health. With advanced age, as well as disease and injury, mobility challenges often become prominent. The COVID-19 breakout and the subsequent lockdowns all over the world put severe restrictions on everyone’s mobility. However, as it turns out, the effect on people’s mobility has not only been negative. For Gottfried Koch (69), who has a previous history of heart disease, the lockdown, combined with watching our video was a small turning point in his life.
Being able to remotely monitor patients’ mobility in their natural environment is a major advantage, both in lockdown and in general. To meet the societal need for better mobility assessment, Mobilise-D will follow up the ongoing technical validation study with a large-scale clinical study that will include 2400 patients from four different cohorts across different sites in Europe.
Mobility is often said to be a sixth vital sign, just as important as other vital signs such as blood pressure and heart rate, and the key to independence in our daily life. But what does mobility actually mean for people? And what happens when they experience mobility loss?
We asked several people what the importance of mobility is for them, and what the impact was when they experienced mobility loss. Here are some of their answers.
Prof. Lynn Rochester and Dr. Ronenn Roubenoff explain how mobility is a vital sign and the benefits of being able to measure people’s mobility in a reliable way. To achieve a robust digital mobility outcome, Mobilise-D will first have to overcome a few challenges. More about this in the video.
Mobilise-D technology for remote monitoring of patients’ daily-life mobility! Interview with Lynn Rochester, Professor of Human Movement Science, Institute of neuroscience, Newcastle University, the Academic Lead of Mobilise-D and Ronenn Roubenoff, Global Head, Translational Medicine Discovery & Profiling, Novartis Institutes for Biomedical Research, the EFPIA Co-lead of Mobilise-D.